サルブタモールAPI（医薬品有効成分）の世界市場レポート2025年

サルブタモールAPI（医薬品有効成分）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.4％で39億米ドルに成長します。予測される成長の背景には、大気環境の悪化、喘息やCOPDの罹患率の増加、ジェネリック医薬品の需要拡大、ヘルスケア支出の増加、ヘルスケアインフラの開発があります。今後数年間に予想される顕著な動向としては、環境に優しい化学プロセスの進歩、自動化生産システムの採用拡大、プロセス分析技術（PAT）の利用強化、定量吸入器技術の革新、個別投与形式の出現などが挙げられます。

呼吸器疾患の罹患率の上昇が、今後数年間のサルブタモールAPI（医薬品有効成分）市場の成長を牽引すると予想されます。呼吸器疾患は肺や気道に影響を及ぼし、呼吸困難や酸素摂取量の減少につながります。これらの疾患には、喘息、慢性閉塞性肺疾患（COPD）、肺炎、気管支炎、その他の肺感染症が含まれます。呼吸器疾患の患者数の増加は、気道に刺激を与え肺機能を損なう有害な汚染物質に個人をさらす大気汚染の増加に大きく起因しています。サルブタモールAPIは、気道の開放を助け、喘鳴や息切れなどの症状を素早く緩和し、全体的な呼吸機能と患者の健康を改善することにより、これらの症状の治療に重要な役割を果たしています。例えば、2024年11月にオーストラリア統計局が発表したところによると、2022年には約280万人のオーストラリア人（人口の約11％）が喘息患者でした。喘息は、2023年には全疾患負担の2.5％、呼吸器疾患負担の35％を占め、1～9歳の小児の疾患負担の主な原因となっています。その結果、呼吸器疾患の有病率の増加がサルブタモールAPIの需要に拍車をかけています。

サルブタモールAPI市場で事業を展開する企業は、環境基準に合わせ、持続可能な治療ソリューションを提供するために、環境に優しい吸入器などの革新的な薬剤製剤にますます注力しています。これらの吸入器は、地球温暖化係数の低い推進剤を利用したり、ドライパウダー吸入器のように推進剤を使用しないシステムとして設計されています。例えば、2023年11月、英国の製薬会社GSK plcは、低炭素吸入器Ventolinを第III相試験に進めました。この吸入器は、排出量を90％削減する次世代推進剤を使用しています。ヴェントリンはサルブタモール（別名アルブテロール）を含む吸入器のブランドで、喘息やその他の呼吸器系の問題を緩和するため、気道を開くことで作用します。同社のサステナビリティ・イニシアチブは、有効成分であるサルブタモールAPIはそのままに、吸入器に使用されるプロペラントを変更して環境への影響を減らすことに重点を置いています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のサルブタモールAPI（医薬品有効成分）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のサルブタモールAPI（医薬品有効成分）市場：成長率分析
• 世界のサルブタモールAPI（医薬品有効成分）市場の実績：規模と成長, 2019-2024
• 世界のサルブタモールAPI（医薬品有効成分）市場の予測：規模と成長, 2024-2029, 2034F
• 世界のサルブタモールAPI（医薬品有効成分）：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のサルブタモールAPI（医薬品有効成分）市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• サルブタモール硫酸塩
• レバルブテロール塩酸塩
• 世界のサルブタモールAPI（医薬品有効成分）市場：剤形タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入ソリューション
• 錠剤製剤
• シロップ製剤
• その他のデリバリー方法
• 世界のサルブタモールAPI（医薬品有効成分）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のサルブタモールAPI（医薬品有効成分）市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 喘息
• 慢性閉塞性肺疾患（COPD）
• 気管支けいれん
• その他の用途
• 世界のサルブタモールAPI（医薬品有効成分）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬会社
• 調査室
• その他のエンドユーザー
• 世界のサルブタモールAPI（医薬品有効成分）市場、サルブタモール硫酸塩、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入粉末
• 吸入液
• 経口錠
• 経口シロップ
• 注射剤
• 世界のサルブタモールAPI（医薬品有効成分）市場、レバルブテロール塩酸塩、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 吸入液
• 定量噴霧式吸入器（MDI）
• 経口溶液
• ネブライザー溶液

第7章 地域別・国別分析

• 世界のサルブタモールAPI（医薬品有効成分）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のサルブタモールAPI（医薬品有効成分）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• サルブタモールAPI（医薬品有効成分）市場：競合情勢
• サルブタモールAPI（医薬品有効成分）市場：企業プロファイル
  • Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • Amphastar Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• FDC Limited
• Neuland Laboratories Ltd.
• Melody Healthcare Pvt. Ltd.
• Supriya Lifescience Ltd.
• Lusochimica S.p.A.
• Intas Pharmaceuticals ltd
• Olon S.p.A.
• VIVAN Life Sciences
• Vamsi Labs Ltd.
• Aarti Pharmalabs Ltd.
• Jayco Chemical Industries
• Orex Pharma Pvt. Ltd.
• Enomark
• Chemcopia
• Cerata Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• サルブタモールAPI（医薬品有効成分）市場2029：新たな機会を提供する国
• サルブタモールAPI（医薬品有効成分）市場2029：新たな機会を提供するセグメント
• サルブタモールAPI（医薬品有効成分）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Salbutamol active pharmaceutical ingredient (API) is the pure, pharmacologically active component that delivers the intended therapeutic effect in medications used for treating respiratory disorders. It serves as the foundational compound utilized by pharmaceutical manufacturers in producing finished dosage forms such as inhalers, tablets, and syrups.

The primary variants of salbutamol active pharmaceutical ingredient (API) include salbutamol sulfate and levalbuterol hydrochloride. Salbutamol sulfate, the sulfate salt form of salbutamol, acts as a rapid-onset bronchodilator, alleviating symptoms of asthma and other obstructive airway conditions by relaxing airway muscles. These APIs are formulated into inhalation solutions, tablets, syrups, and other dosage forms and are made available through hospital pharmacies, retail pharmacies, and online platforms. They are indicated for conditions such as asthma, chronic obstructive pulmonary disease (COPD), bronchospasm, among others, and are used by end-users like pharmaceutical companies, research institutions, and others.

The salbutamol active pharmaceutical ingredient (API) market research report is one of a series of new reports from The Business Research Company that provides salbutamol active pharmaceutical ingredient (API) market statistics, including the salbutamol industry global market size, regional shares, competitors with the salbutamol active pharmaceutical ingredient (API) market share, detailed salbutamol active pharmaceutical ingredient (API) market segments, market trends, and opportunities, and any further data you may need to thrive in the salbutamol active pharmaceutical ingredient (API) industry. This salbutamol active pharmaceutical ingredient (API) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salbutamol active pharmaceutical ingredient (API) market size has grown strongly in recent years. It will grow from $2.86 billion in 2024 to $3.05 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The expansion during the historical period was supported by a growing prevalence of respiratory illnesses, an aging demographic, increased availability of generic medications, a rise in healthcare infrastructure, and heightened levels of environmental pollution.

The salbutamol active pharmaceutical ingredient (API) market size is expected to see strong growth in the next few years. It will grow to $3.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The projected growth is attributed to worsening air quality, increasing rates of asthma and COPD, escalating demand for generics, growing healthcare spending, and the development of healthcare infrastructure. Prominent trends anticipated in the coming years include progress in eco-friendly chemical processes, greater adoption of automated production systems, enhanced use of process analytical technology (PAT), innovations in metered-dose inhaler technologies, and the emergence of individualized dosing formats.

The rising incidence of respiratory diseases is expected to drive the growth of the salbutamol active pharmaceutical ingredient (API) market in the coming years. Respiratory conditions affect the lungs and airways, leading to breathing difficulties and reduced oxygen intake. These conditions include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and other lung infections. The growing number of respiratory cases is largely attributed to increasing air pollution, which exposes individuals to harmful pollutants that irritate the airways and impair lung function. Salbutamol API plays a vital role in treating these conditions by helping to open the airways, providing quick relief from symptoms such as wheezing and shortness of breath, and improving overall respiratory function and patient health. For example, in November 2024, the Australian Bureau of Statistics reported that in 2022, approximately 2.8 million Australians-about 11% of the population-were living with asthma. Asthma accounted for 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023, making it the leading cause of disease burden among children aged 1-9 years. Consequently, the increasing prevalence of respiratory diseases is fueling the demand for salbutamol API.

Companies operating in the salbutamol API market are increasingly focusing on innovative drug formulations, such as eco-friendly inhalers, to align with environmental standards and offer sustainable treatment solutions. These inhalers utilize propellants with low global warming potential or are designed as propellant-free systems, such as dry powder inhalers. For instance, in November 2023, GSK plc, a UK-based pharmaceutical company, advanced its low-carbon Ventolin inhaler to Phase III trials. This inhaler uses a next-generation propellant that reduces emissions by 90%. Ventolin is a brand of inhalers containing salbutamol (also known as albuterol), which works by opening the airways to provide relief from asthma and other respiratory issues. The company's sustainability initiative focuses on modifying the propellant used in the inhaler to reduce its environmental impact, while maintaining the same active ingredient-salbutamol API.

In October 2022, Lupin Limited, an India-based pharmaceutical company, acquired the rights to Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol from Sunovion Pharmaceuticals Inc. for $75 million. This acquisition enhances Lupin's respiratory product portfolio in the US market, strengthening its presence in the inhalation therapy segment and improving its capability to support patients with chronic respiratory conditions. Sunovion Pharmaceuticals Inc. is a US-based firm known for its expertise in respiratory treatments, including those based on the salbutamol active pharmaceutical ingredient (API) for asthma and COPD.

Major players in the salbutamol active pharmaceutical ingredient (api) market are Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Amphastar Pharmaceuticals Inc., FDC Limited, Neuland Laboratories Ltd., Melody Healthcare Pvt. Ltd., Supriya Lifescience Ltd., Lusochimica S.p.A., Intas Pharmaceuticals ltd, Olon S.p.A., VIVAN Life Sciences, Vamsi Labs Ltd., Aarti Pharmalabs Ltd., Jayco Chemical Industries, Orex Pharma Pvt. Ltd., Enomark, Chemcopia, and Cerata Pharma.

North America was the largest region in the salbutamol active pharmaceutical ingredient (API) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in salbutamol active pharmaceutical ingredient (API) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salbutamol active pharmaceutical ingredient (API) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The salbutamol active pharmaceutical ingredient (API) market consists of sales of nebulizer solutions, raw salbutamol powder, and injectable salbutamol formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Salbutamol active pharmaceutical ingredient (API) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on salbutamol active pharmaceutical ingredient (api) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for salbutamol active pharmaceutical ingredient (api) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The salbutamol active pharmaceutical ingredient (api) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Salbutamol Sulfate; Levalbuterol Hydrochloride
• 2) By Formulation Type: Inhalation Solutions; Tablet Formulations; Syrup Formulations; Other Delivery Methods
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Asthma; Chronic Obstructive Pulmonary Disease (COPD); Bronchospasm; Other Applications
• 5) By End-User: Pharmaceutical Companies; Research Laboratories; Other End Users
• Subsegments:
• 1) By Salbutamol Sulfate: Inhalation Powder; Inhalation Solution; Oral Tablets; Oral Syrup; Injectable Form
• 2) By Levalbuterol Hydrochloride: Inhalation Solution; Metered Dose Inhaler (MDI); Oral Solution; Nebulizer Solution
• Companies Mentioned: Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Limited; Amphastar Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Salbutamol Active Pharmaceutical Ingredient (API) Market Characteristics

3. Salbutamol Active Pharmaceutical Ingredient (API) Market Trends And Strategies

4. Salbutamol Active Pharmaceutical Ingredient (API) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Salbutamol Active Pharmaceutical Ingredient (API) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Salbutamol Active Pharmaceutical Ingredient (API) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Growth Rate Analysis
• 5.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Salbutamol Active Pharmaceutical Ingredient (API) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Salbutamol Active Pharmaceutical Ingredient (API) Total Addressable Market (TAM)

6. Salbutamol Active Pharmaceutical Ingredient (API) Market Segmentation

• 6.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salbutamol Sulfate
• Levalbuterol Hydrochloride
• 6.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Solutions
• Tablet Formulations
• Syrup Formulations
• Other Delivery Methods
• 6.3. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Bronchospasm
• Other Applications
• 6.5. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical Companies
• Research Laboratories
• Other End Users
• 6.6. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Salbutamol Sulfate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Powder
• Inhalation Solution
• Oral Tablets
• Oral Syrup
• Injectable Form
• 6.7. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Sub-Segmentation Of Levalbuterol Hydrochloride, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inhalation Solution
• Metered Dose Inhaler (MDI)
• Oral Solution
• Nebulizer Solution

7. Salbutamol Active Pharmaceutical Ingredient (API) Market Regional And Country Analysis

• 7.1. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Salbutamol Active Pharmaceutical Ingredient (API) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market

• 8.1. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Salbutamol Active Pharmaceutical Ingredient (API) Market

• 9.1. China Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 9.2. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Salbutamol Active Pharmaceutical Ingredient (API) Market

• 10.1. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market

• 11.1. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 11.2. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 12.1. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 13.1. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market

• 14.1. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 14.2. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 15.1. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 15.2. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Salbutamol Active Pharmaceutical Ingredient (API) Market

• 16.1. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market

• 17.1. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Salbutamol Active Pharmaceutical Ingredient (API) Market

• 18.1. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market

• 19.1. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market

• 20.1. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market

• 21.1. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 21.2. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market

• 22.1. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 23.1. North America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 23.2. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Salbutamol Active Pharmaceutical Ingredient (API) Market

• 24.1. USA Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 24.2. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market

• 25.1. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 25.2. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Salbutamol Active Pharmaceutical Ingredient (API) Market

• 26.1. South America Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 26.2. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market

• 27.1. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market

• 28.1. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 28.2. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market

• 29.1. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market Overview
• 29.2. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Formulation Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Salbutamol Active Pharmaceutical Ingredient (API) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape And Company Profiles

• 30.1. Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Landscape
• 30.2. Salbutamol Active Pharmaceutical Ingredient (API) Market Company Profiles
  • 30.2.1. Aurobindo Pharma Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Cipla Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amphastar Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Salbutamol Active Pharmaceutical Ingredient (API) Market Other Major And Innovative Companies

• 31.1. FDC Limited
• 31.2. Neuland Laboratories Ltd.
• 31.3. Melody Healthcare Pvt. Ltd.
• 31.4. Supriya Lifescience Ltd.
• 31.5. Lusochimica S.p.A.
• 31.6. Intas Pharmaceuticals ltd
• 31.7. Olon S.p.A.
• 31.8. VIVAN Life Sciences
• 31.9. Vamsi Labs Ltd.
• 31.10. Aarti Pharmalabs Ltd.
• 31.11. Jayco Chemical Industries
• 31.12. Orex Pharma Pvt. Ltd.
• 31.13. Enomark
• 31.14. Chemcopia
• 31.15. Cerata Pharma

32. Global Salbutamol Active Pharmaceutical Ingredient (API) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Salbutamol Active Pharmaceutical Ingredient (API) Market

34. Recent Developments In The Salbutamol Active Pharmaceutical Ingredient (API) Market

35. Salbutamol Active Pharmaceutical Ingredient (API) Market High Potential Countries, Segments and Strategies

• 35.1 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Salbutamol Active Pharmaceutical Ingredient (API) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer